Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of December 2022, with a filing date of December 14, 2022. The report primarily serves to announce that the Company has regained compliance with Nasdaq listing rules.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding listing status rather than a financial results report.
Material Changes
The material change reported is the restoration of compliance with Nasdaq listing requirements, as detailed in the press release dated December 12, 2022, which is incorporated by reference as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the context of the listing compliance issue. No unusual items or contingencies are described in the text provided.
Investor Verification Checklist
- Verify the specific Nasdaq listing rule that was previously violated and the steps taken to achieve compliance.
- Review the full text of the press release (Exhibit 99.1) for details on the compliance mechanism.
- Confirm the current trading status of the Company's securities on Nasdaq.
- Note the discrepancy between the requested company name (Scinai Immunotherapeutics Ltd.) and the actual filer (BiondVax Pharmaceuticals Ltd.).